In just a few weeks, BLOODPAC will host our fifth Annual New Frontiers seminar titled "Molecular Residual Disease in Hematologic Cancers: Progress, Challenges, and Future Directions." The event will take place on December 9th from 1:00–3:00 PM ET, and you can register using this link.

This year's New Frontiers Seminar will focus on the evolving role of molecular residual disease (MRD) in hematologic cancers and the opportunities and challenges that lie ahead. Join experts from across the field for a forward-looking discussion on current applications of MRD, key scientific and clinical gaps, unmet needs in implementation and standardization, and collaborative pathways to advance research and improve patient outcomes.

Confirmed speakers currently include:

• Ash A. Alizadeh, MD, PhD, Moghadam Family Professor of Medicine, Divisions of Oncology & Hematology, Dept of Medicine, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine

• Christopher S. Hourigan, DM DPhil, Director, Virginia Tech FBRI Cancer Research Center

• Mark Roschewski, MD, Attending Physician, Memorial Sloan Kettering Cancer Center (MSKCC)

• Mehrdad Mobasher, MD, Executive Partner, Institute for Follicular Lymphoma Innovation (IFLI)

• Nicole Gormley, MD, Founder, Gormley Advisory LLC

• Paul Fisher, PhD, Director of Translational Science, Allogene Therapeutics

• Sara Hersey, MS, MBA, VP and Head of Precision Medicine, Bristol Myers Squibb (BMS)

• Sugganth Pillei, MD, MBA, Director of Molecular Oncology and Pathology Services, NeoGenomics 

We hope you are able to join us on December 9th!